Bielicki Julia Anna, Lundin Rebecca, Sharland Mike
From the *Paediatric Infectious Diseases Research Group, St George's University of London, London, United Kingdom; and †PENTA Foundation, Padova, Italy.
Pediatr Infect Dis J. 2015 Jul;34(7):734-41. doi: 10.1097/INF.0000000000000652.
Surveillance of antimicrobial resistance (AMR) is central for defining appropriate strategies to deal with changing AMR levels. It is unclear whether childhood AMR patterns differ from those detected in isolates from adult patients.
Resistance percentages of nonduplicate Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa bloodstream isolates from children less than 18 years of age reported to the Antibiotic Resistance and Prescribing in European Children (ARPEC) project were compared with all-age resistance percentages reported by the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the same pathogen-antibiotic class combinations, period and countries. In addition, resistance percentages were compared between ARPEC isolates from children less than 1 year of age and children greater than or equal to1 year of age.
Resistance percentages for many important pathogen-antibiotic class combinations were different for ARPEC isolates compared with EARS-Net. E. coli and K. pneumoniae fluoroquinolone resistance percentages were substantially lower in ARPEC (13.4% and 17.9%) than in EARS-Net (23.0% and 30.7%), whereas the reverse was true for all pathogen-antibiotic class combinations in P. aeruginosa (for example, 27.3% aminoglycoside resistance in ARPEC, 19.3% in EARS-Net, 32.8% carbapenem resistance in ARPEC and 20.5% in EARS-Net), and for S. pneumoniae and macrolide resistance. For many Gram-negative pathogen-antibiotic class combinations, isolates from children greater than or equal to 1 year of age showed higher resistance percentages than isolates from children less than 1 year of age.
Age-stratified presentation of resistance percentage estimates by surveillance programs will allow identification of important variations in resistance patterns between different patient groups for targeted intervention.
监测抗菌药物耐药性(AMR)是确定应对不断变化的AMR水平的适当策略的核心。尚不清楚儿童的AMR模式是否与成年患者分离株中检测到的模式不同。
将欧洲儿童抗生素耐药性与处方(ARPEC)项目报告的18岁以下儿童非重复金黄色葡萄球菌、肺炎链球菌、粪肠球菌、屎肠球菌、大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌血流分离株的耐药百分比,与欧洲抗菌药物耐药性监测网络(EARS-Net)报告的相同病原体-抗生素类别组合、时期和国家的全年龄耐药百分比进行比较。此外,还比较了ARPEC中1岁以下儿童分离株和1岁及以上儿童分离株的耐药百分比。
与EARS-Net相比,ARPEC分离株的许多重要病原体-抗生素类别组合的耐药百分比不同。ARPEC中大肠埃希菌和肺炎克雷伯菌对氟喹诺酮类的耐药百分比(分别为13.4%和17.9%)显著低于EARS-Net(分别为23.0%和30.7%),而铜绿假单胞菌的所有病原体-抗生素类别组合情况则相反(例如,ARPEC中氨基糖苷类耐药率为27.3%,EARS-Net中为19.3%;ARPEC中碳青霉烯类耐药率为32.8%,EARS-Net中为20.5%),肺炎链球菌和大环内酯类耐药情况也是如此。对于许多革兰氏阴性病原体-抗生素类别组合,1岁及以上儿童的分离株耐药百分比高于1岁以下儿童的分离株。
监测项目按年龄分层呈现耐药百分比估计值,将有助于识别不同患者群体之间耐药模式的重要差异,以便进行有针对性的干预。